Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.
Type
Public
HQ
Warren, US
Founded
2009
Size (employees)
22 (est)
Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, US
Report incorrect company information

Bellerophon Therapeutics Office Locations

Bellerophon Therapeutics has an office in Warren
Warren, US (HQ)
302 184 Liberty Corner Rd
Show all (1)
Report incorrect company information

Bellerophon Therapeutics Financials and Metrics

Bellerophon Therapeutics Financials

USD

Net income (Q1, 2018)

4.1 m

EBIT (Q1, 2018)

(8.5 m)

Market capitalization (22-Jun-2018)

164.9 m

Closing share price (22-Jun-2018)

2.9

Cash (31-Mar-2018)

28.4 m
Bellerophon Therapeutics's current market capitalization is $164.9 m.
Annual
USDFY, 2016

General and administrative expense

2.2 m

R&D expense

5.1 m

Operating expense total

7.3 m

EBIT

(7.3 m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

General and administrative expense

4.6 m3.4 m4.3 m2 m1.2 m1.7 m1.4 m2.1 m

R&D expense

9.5 m8.4 m7.1 m5.1 m4 m2.5 m3.3 m6.4 m

Operating expense total

14.1 m11.9 m11.4 m7.1 m5.2 m4.2 m4.8 m8.5 m

EBIT

(12.9 m)(11.6 m)(11.2 m)(7.1 m)(5.2 m)(4.2 m)(4.8 m)(8.5 m)
Annual
USDFY, 2016

Cash

14.5 m

Current Assets

26.5 m

PP&E

1.4 m

Total Assets

29.7 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Cash

62.9 m48.5 m23.9 m1.3 m1.3 m3.9 m13.5 m28.4 m

Current Assets

73.6 m60.9 m46.9 m23.1 m18.6 m17.5 m23.2 m34.8 m

PP&E

1.6 m1.5 m1.8 m1.7 m1.6 m1.5 m1.3 m935 k

Total Assets

75.2 m62.4 m49.2 m31.2 m26.3 m22.8 m25.8 m35.9 m
Annual
USDFY, 2016

Net Income

(23.8 m)

Depreciation and Amortization

(400 k)

Cash From Operating Activities

(17.2 m)

Cash From Investing Activities

12.2 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(12.9 m)(11.6 m)(11.1 m)(7.1 m)(5.1 m)(4.2 m)(19.1 m)4.1 m

Depreciation and Amortization

91 k

Accounts Payable

659 k966 k934 k641 k2 m2.2 m3.9 m

Cash From Operating Activities

(444 k)
USDY, 2018

Financial Leverage

16.2 x
Show all financial metrics
Report incorrect company information